目的:这项研究的目的是比较事件人群的差异,合并症,以及新诊断的早发性(T2DM)和晚发性T2DM患者之间的降糖药物处方,为临床实践提供现实世界的证据。
方法:本研究基于上海医院链接数据库(SHLD)。本研究包括2013年至2021年的匿名电子病历(EHR)数据。新诊断的T2DM患者被定义为在过去三年中没有相关诊断记录或降糖药物处方的患者。早发性T2DM定义为在T2DM首次就诊时年龄为18-40岁的患者,代表1980年代以后出生的患者。晚发性T2DM被定义为65-80岁的人群,代表出生在相对不发达时期的人群。
结果:本研究共纳入35457例新诊断的早发性T2DM患者和149108例新诊断的晚发性T2DM患者。与晚发型T2DM患者相比,更多的早发型T2DM患者在首次就诊时出现血脂异常(9.5%V.S.7.7%,P<0.01),尽管他们的年龄差异显着。早发型T2DM患者更有可能使用二甲双胍,DDP-4i,TZD,SGLT2-i,GLP-1RA在他们第一次访问医院。
结论:早发性T2DM和晚发性T2DM患者的特征不同。与晚发型T2DM患者相比,早发型T2DM患者更容易出现血脂异常,并有新型的器官保护药物.
UNASSIGNED: The aim of this study was to compare the differences in incident population, comorbidities, and glucose-lowering drug prescriptions between newly diagnosed patients with early-onset type 2 diabetes mellitus (T2DM) and those with late-onset T2DM to provide real-world evidence for clinical practice.
UNASSIGNED: This study was based on the Shanghai Hospital Link Database (SHLD). Anonymized electronic medical record (EHR) data from 2013 to 2021 were included in this study. Newly diagnosed patients with T2DM were defined as those without related diagnostic records or glucose-lowering medicine prescriptions in the past 3 years. Early-onset T2DM was defined as patients who were aged 18-40 years old at the first visit for T2DM to represent those who were born after the 1980s. And late-onset T2DM was defined as those aged 65-80 years old to represent those who were born in a relatively undeveloped period. Descriptive statistical analyses were performed to describe their incidence number, glucose-lowering drug prescriptions, and comorbidities at the first visit to the hospital between two T2DM groups.
UNASSIGNED: There were a total of 35,457 newly diagnosed patients with early-onset T2DM and 149,108 newly diagnosed patients with late-onset T2DM included in this study. Patients with late-onset T2DM constituted the majority and their number increased by 2.5% on average by years, while the number of patients with early-onset T2DM remained stable each year. Compared with late-onset T2DM patients, more early-onset T2DM patients had dyslipidemia at the first visit to hospitals (9.5% vs 7.7%, P < 0.01) despite their significant age differences. Patients with early-onset T2DM were more likely to use metformin (74.8% vs 46.5, P < 0.01), dipeptidyl peptidase-4 inhibitors (DDP-4i) (16.7% vs 11.2%, P < 0.01), thiazolidinediones (TZD) (14.9% vs 8.4%, P < 0.01), sodium glucose cotransporter 2 inhibitors (SGLT2-i) (0.8% vs 0.3%, P < 0.01), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) (3.7% vs 0.5%, P < 0.01) at their first visit to the hospital.
UNASSIGNED: Different characteristics were observed between patients with early-onset T2DM and those with late-onset T2DM. Compared with patients with late-onset T2DM, those with early-onset T2DM were more prone to dyslipidemia and had novel organ-protective drugs prescribed.